JP2016020389A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016020389A5 JP2016020389A5 JP2015208653A JP2015208653A JP2016020389A5 JP 2016020389 A5 JP2016020389 A5 JP 2016020389A5 JP 2015208653 A JP2015208653 A JP 2015208653A JP 2015208653 A JP2015208653 A JP 2015208653A JP 2016020389 A5 JP2016020389 A5 JP 2016020389A5
- Authority
- JP
- Japan
- Prior art keywords
- mmp9
- binding protein
- chain polypeptide
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37788610P | 2010-08-27 | 2010-08-27 | |
| US61/377,886 | 2010-08-27 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013526186A Division JP5878538B2 (ja) | 2010-08-27 | 2011-08-26 | マトリクスメタロプロティナーゼ９に対する抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017159712A Division JP6435381B2 (ja) | 2010-08-27 | 2017-08-22 | マトリクスメタロプロティナーゼ９に対する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016020389A JP2016020389A (ja) | 2016-02-04 |
| JP2016020389A5 true JP2016020389A5 (enExample) | 2016-05-19 |
| JP6198797B2 JP6198797B2 (ja) | 2017-09-20 |
Family
ID=45724100
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013526186A Active JP5878538B2 (ja) | 2010-08-27 | 2011-08-26 | マトリクスメタロプロティナーゼ９に対する抗体 |
| JP2015208653A Active JP6198797B2 (ja) | 2010-08-27 | 2015-10-23 | マトリクスメタロプロティナーゼ９に対する抗体 |
| JP2017159712A Active JP6435381B2 (ja) | 2010-08-27 | 2017-08-22 | マトリクスメタロプロティナーゼ９に対する抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013526186A Active JP5878538B2 (ja) | 2010-08-27 | 2011-08-26 | マトリクスメタロプロティナーゼ９に対する抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017159712A Active JP6435381B2 (ja) | 2010-08-27 | 2017-08-22 | マトリクスメタロプロティナーゼ９に対する抗体 |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US8377443B2 (enExample) |
| EP (1) | EP2608809B1 (enExample) |
| JP (3) | JP5878538B2 (enExample) |
| KR (4) | KR101827048B1 (enExample) |
| CN (2) | CN103140240B (enExample) |
| AP (2) | AP3948A (enExample) |
| AU (1) | AU2011293125B2 (enExample) |
| BR (1) | BR112013004579B1 (enExample) |
| CA (1) | CA2808418C (enExample) |
| CL (1) | CL2013000535A1 (enExample) |
| CO (1) | CO6680656A2 (enExample) |
| CR (1) | CR20130132A (enExample) |
| EA (1) | EA031729B1 (enExample) |
| EC (1) | ECSP13012525A (enExample) |
| ES (1) | ES2739505T3 (enExample) |
| IL (2) | IL224614A (enExample) |
| MA (1) | MA34527B1 (enExample) |
| MX (1) | MX342413B (enExample) |
| NZ (2) | NZ701444A (enExample) |
| PE (1) | PE20131376A1 (enExample) |
| PH (2) | PH12013500347A1 (enExample) |
| PL (1) | PL2608809T3 (enExample) |
| PT (1) | PT2608809T (enExample) |
| SG (2) | SG10201506703VA (enExample) |
| SI (1) | SI2608809T1 (enExample) |
| TR (1) | TR201910348T4 (enExample) |
| UA (1) | UA109908C2 (enExample) |
| WO (1) | WO2012027721A2 (enExample) |
| ZA (2) | ZA201301338B (enExample) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101827048B1 (ko) | 2010-08-27 | 2018-02-07 | 길리아드 바이오로직스, 인크. | 매트릭스 메탈로프로테이나제 ９에 대한 항체 |
| EP3252076B1 (en) | 2011-01-14 | 2019-09-04 | The Regents Of The University Of California | Diagnostic use of antibodies against ror-1 protein |
| US9550836B2 (en) * | 2012-02-29 | 2017-01-24 | Gilead Biologics, Inc. | Method of detecting human matrix metalloproteinase 9 using antibodies |
| NZ629178A (en) * | 2012-02-29 | 2016-09-30 | Gilead Biologics Inc | Antibodies to matrix metalloproteinase 9 |
| BR112015025390A2 (pt) * | 2013-04-05 | 2017-08-29 | Zylberberg Claudia | Composição, métodos para isolar célula tronco, para tratar um indivíduo e um paciente, para reduzir um depósito de gordura, para dissociar um tecido e uma matriz de proteína, para tratar ou curar uma cicatriz ou uma ferida, e para isolar células ilhotas, vetor de expressão, composição farmacêutica, formulação de liberação temporizada, e, kit |
| US20150148345A1 (en) | 2013-11-26 | 2015-05-28 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| CA2937320A1 (en) | 2014-01-20 | 2015-07-23 | Gilead Sciences, Inc. | Therapies for treating cancers |
| EP2985296A1 (en) * | 2014-08-13 | 2016-02-17 | Calypso Biotech SA | Antibodies specific for MMP9 |
| EP2985295A1 (en) * | 2014-08-13 | 2016-02-17 | Calypso Biotech SA | Antibodies specific for MMP9 |
| TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| PL3097102T3 (pl) | 2015-03-04 | 2018-04-30 | Gilead Sciences Inc | Związki 4,6-diamino-pirydo[3,2-d]pirymidyny modulujące działanie receptora toll-podobnego |
| CN105037553B (zh) * | 2015-08-20 | 2018-04-17 | 内蒙古蒙元生物基因科技有限公司 | 一种能够检测癌症的免疫球蛋白 |
| TW201725044A (zh) | 2015-10-01 | 2017-07-16 | 基利科學股份有限公司 | 用於治療癌症之btk抑制劑及查核點抑制劑之組合 |
| US20170174788A1 (en) * | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders |
| CU20180059A7 (es) | 2015-12-17 | 2018-10-04 | Gilead Sciences Inc | Compuestos inhibidores de la quinasa de unión a tank |
| CA3016081A1 (en) | 2016-03-04 | 2017-09-08 | Gilead Sciences, Inc. | Compositions and combinations of autotaxin inhibitors |
| CA3019003A1 (en) | 2016-04-08 | 2017-10-12 | Gilead Sciences, Inc. | Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases |
| JP6730466B2 (ja) | 2016-06-13 | 2020-07-29 | アイ−エムエービー バイオファーマ ユーエス リミテッド | 抗ｐｄ−ｌ１抗体およびその使用 |
| WO2018014111A1 (en) | 2016-06-22 | 2018-01-25 | Harless William Warren | Cancer treatment and metastasis inhibition using an anti-cancer stem cell agent in combination with a neul sialidase inhibitor or a cytokine inhibitor after primary cancer treatment |
| EP3493797A1 (en) | 2016-08-04 | 2019-06-12 | Gilead Sciences, Inc. | Cobicistat for use in cancer treatments |
| KR102268448B1 (ko) | 2016-09-02 | 2021-06-22 | 길리애드 사이언시즈, 인코포레이티드 | 톨 유사 수용체 조정제 화합물 |
| ES2826748T3 (es) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll |
| WO2018085069A1 (en) | 2016-11-03 | 2018-05-11 | Gilead Sciences, Inc. | Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer |
| US20180141939A1 (en) | 2016-11-22 | 2018-05-24 | Gilead Sciences, Inc. | Solid forms of a bet inhibitor |
| BR112019012253A2 (pt) | 2016-12-16 | 2020-01-28 | Centre Hospitalier Univ Bordeaux | inibidores de mmp9 e usos dos mesmos na prevenção ou tratamento de um transtorno de despigmentação |
| PL3383916T3 (pl) | 2017-01-24 | 2023-06-12 | I-Mab Biopharma Us Limited | Przeciwciała anty-cd73 i ich zastosowania |
| JP2020508326A (ja) | 2017-02-24 | 2020-03-19 | ギリアド サイエンシズ， インコーポレイテッド | ブルトン型チロシンキナーゼの阻害剤 |
| AR110998A1 (es) | 2017-02-24 | 2019-05-22 | Gilead Sciences Inc | Inhibidores de la tirosina cinasa de bruton |
| US10941178B2 (en) | 2017-03-17 | 2021-03-09 | Gilead Sciences, Inc. | Method of purifying an antibody |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| JP7109440B2 (ja) | 2017-07-18 | 2022-07-29 | 第一三共株式会社 | 活性型ｍｍｐ－９結合ペプチド |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| JP2021523151A (ja) | 2018-05-11 | 2021-09-02 | ホスホレックス、インコーポレイテッド | 負の表面電荷を有するマイクロ粒子及びナノ粒子 |
| US10703733B2 (en) | 2018-05-14 | 2020-07-07 | Gilead Sciences, Inc. | MCL-1 inhibitors |
| BR112020026746A2 (pt) | 2018-07-13 | 2021-03-30 | Gilead Sciences, Inc. | Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição. |
| US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
| CN112955435B (zh) | 2018-10-24 | 2024-09-06 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| FI3873903T3 (fi) | 2018-10-31 | 2024-03-26 | Gilead Sciences Inc | Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| CA3129011C (en) | 2019-03-07 | 2023-12-19 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| MX2021015452A (es) | 2019-06-25 | 2022-02-11 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso. |
| MX2022004370A (es) | 2019-10-18 | 2022-05-06 | Forty Seven Inc | Terapias de combinacion para tratar sindromes mielodisplasicos y leucemia mieloide aguda. |
| WO2021087064A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| JP7711068B2 (ja) | 2019-12-24 | 2025-07-22 | カルナバイオサイエンス株式会社 | ジアシルグリセロールキナーゼ調節化合物 |
| IL295023A (en) | 2020-02-14 | 2022-09-01 | Jounce Therapeutics Inc | Antibodies and fusion proteins that bind to ccr8 and their uses |
| CR20220547A (es) | 2020-05-01 | 2022-12-15 | Gilead Sciences Inc | Compuestos de 2,4-dioxopirimidina inhibidores de cd73 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240025616A (ko) | 2021-06-23 | 2024-02-27 | 길리애드 사이언시즈, 인코포레이티드 | 다이아실글리세롤 키나제 조절 화합물 |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023278491A1 (en) * | 2021-06-28 | 2023-01-05 | Releviate, Llc | Mmp-9 antibodies and uses thereof |
| JP2024539252A (ja) | 2021-10-28 | 2024-10-28 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジジン－３（２ｈ）－オン誘導体 |
| CA3235986A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Science, Inc. | Cd73 compounds |
| WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| US20230203202A1 (en) | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| EP4667056A1 (en) | 2021-12-22 | 2025-12-24 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| LT4245756T (lt) | 2022-03-17 | 2024-11-25 | Gilead Sciences, Inc. | Ikaros cinko pirštų šeimos skaidymo medžiagos ir jų panaudojimas |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| US20230374036A1 (en) | 2022-04-21 | 2023-11-23 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| IL317958A (en) | 2022-07-01 | 2025-02-01 | Gilead Sciences Inc | CD73 compounds |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| EP4695260A1 (en) | 2023-04-11 | 2026-02-18 | Gilead Sciences, Inc. | Kras modulating compounds |
| KR20250175331A (ko) | 2023-04-21 | 2025-12-16 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| AU2024300557A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025076280A1 (en) * | 2023-10-05 | 2025-04-10 | Ashibio, Inc. | Methods and compositions for treating mmp-9 mediated disorders |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025264572A1 (en) | 2024-06-17 | 2025-12-26 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN119023961B (zh) * | 2024-08-27 | 2026-02-03 | 首都医科大学附属北京朝阳医院 | 用于检测干眼病生物标志物的试剂及其制备方法和用途 |
| CN119060188B (zh) * | 2024-08-30 | 2025-09-12 | 武汉爱博泰克生物科技有限公司 | 抗人基质金属蛋白酶9抗体、抗体对和检测试剂盒 |
| US12510542B1 (en) * | 2025-06-18 | 2025-12-30 | MİMARK Diagnostics, S.L. | Capture antibody and detection antibody binding MMP9 protein |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
| DE69412466T2 (de) | 1993-11-30 | 1999-04-29 | Fuji Yakuhin Kogyo K.K., Takaoka, Toyama | Neue metalloprotease und kodierende dna dafür |
| US5612030A (en) * | 1995-01-17 | 1997-03-18 | University Of Kentucky Research Foundation | Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
| AU770718B2 (en) * | 1998-06-05 | 2004-02-26 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to CD38 to treat multiple myeloma |
| US7101975B1 (en) | 1999-07-13 | 2006-09-05 | University Of Southern California | Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins |
| CA2379373A1 (en) | 1999-07-13 | 2001-01-18 | University Of Southern California | Novel method and composition for inhibition of angiogenesis using antagonists based on mmp-9 and .beta.1 integrins |
| WO2002066057A2 (en) | 2001-02-23 | 2002-08-29 | Biophage Inc. | Methods and compositions for preventing and treating neutrophil-mediated diseases |
| SE0102298D0 (sv) | 2001-06-27 | 2001-06-27 | Astrazeneca Ab | Crystal structure of enzyme and uses thereof |
| WO2003006006A1 (en) | 2001-07-09 | 2003-01-23 | The Regents Of The University Of California | Use of matrix metalloproteinase inhibitors to mitigate nerve damage |
| AU2002352089A1 (en) | 2001-11-23 | 2003-06-10 | Universite Catholique De Louvain | Medical use of antibodies directed against human matrix metalloproteinases or related tissue proteinases for the treatment of abnormal uterine bleeding and endometriosis |
| AU2003270330B2 (en) | 2002-09-06 | 2009-07-30 | Alexion Pharmaceuticals, Inc. | Method of treatment of asthma using antibodies to complement component C5 |
| WO2004076614A2 (de) | 2003-02-27 | 2004-09-10 | Bernd Hinzmann | Humane nukleinsäuresequenzen aus prostatakarzinomen |
| EP1610678B1 (en) | 2003-04-04 | 2011-07-27 | Yeda Research And Development Co., Ltd. | Antibodies for inhibiting the activity of mmp-2 and mmp-9 |
| WO2006037513A1 (en) | 2004-10-09 | 2006-04-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with matrix metalloproteinase 9 (mmp9) |
| EP1904846A4 (en) | 2005-06-29 | 2009-03-18 | Rules Based Medicine Inc | METHOD AND KITS FOR THE DIAGNOSIS OF ACUTE CORONARY SYNDROME |
| EP1957540B1 (en) | 2005-12-02 | 2012-06-13 | Genentech, Inc. | Binding polypeptides and uses thereof |
| WO2007144781A2 (en) | 2006-04-21 | 2007-12-21 | Diagnotech Pty. Ltd. | Diagnostic methods and kits utilizing antibodies for metalloproteases |
| WO2008088864A2 (en) | 2007-01-18 | 2008-07-24 | The Trustess Of Columbia University In The City Of New York | Matrix metalloproteinase-9-related methods |
| EP2155691B1 (en) * | 2007-02-23 | 2016-01-13 | Yeda Research and Development Co. Ltd. | Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins |
| PE20090765A1 (es) | 2007-06-08 | 2009-07-10 | Irm Llc | Metodos y composiciones para inducir la apoptosis en celulas cancerosas |
| KR20100071972A (ko) | 2007-08-15 | 2010-06-29 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Ｍｍｐ-9의 조절인자 및 그의 용도 |
| US8147836B2 (en) | 2007-12-17 | 2012-04-03 | Dyax Corp. | Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins |
| JP2011517320A (ja) * | 2008-03-03 | 2011-06-02 | ダイアックス コーポレーション | メタロプロテアーゼ９結合タンパク質およびメタロプロテアーゼ２結合タンパク質 |
| WO2009111450A2 (en) * | 2008-03-03 | 2009-09-11 | Dyax Corp. | Metalloproteinase 9 binding proteins |
| US20110262396A1 (en) | 2008-10-22 | 2011-10-27 | Dyax Corp. | Combination treatments comprising protease binding proteins for inflammatory disorders |
| WO2010059543A1 (en) | 2008-11-20 | 2010-05-27 | Merck Sharp & Dohme Corp. | Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use |
| EA201270701A1 (ru) | 2010-01-27 | 2013-01-30 | Йеда Рисеч Энд Девелопмент Ко. Лтд. | Ингибирующие металлопротеины антитела |
| US20110261695A1 (en) * | 2010-04-23 | 2011-10-27 | Xiaoming Zhao | System and method for network congestion control |
| KR101827048B1 (ko) | 2010-08-27 | 2018-02-07 | 길리아드 바이오로직스, 인크. | 매트릭스 메탈로프로테이나제 ９에 대한 항체 |
| NZ629178A (en) | 2012-02-29 | 2016-09-30 | Gilead Biologics Inc | Antibodies to matrix metalloproteinase 9 |
| US9550836B2 (en) | 2012-02-29 | 2017-01-24 | Gilead Biologics, Inc. | Method of detecting human matrix metalloproteinase 9 using antibodies |
-
2011
- 2011-08-26 KR KR1020147035325A patent/KR101827048B1/ko active Active
- 2011-08-26 KR KR1020187002896A patent/KR101881724B1/ko active Active
- 2011-08-26 CN CN201180041422.8A patent/CN103140240B/zh active Active
- 2011-08-26 EA EA201390146A patent/EA031729B1/ru not_active IP Right Cessation
- 2011-08-26 JP JP2013526186A patent/JP5878538B2/ja active Active
- 2011-08-26 SG SG10201506703VA patent/SG10201506703VA/en unknown
- 2011-08-26 PL PL11820759T patent/PL2608809T3/pl unknown
- 2011-08-26 UA UAA201302088A patent/UA109908C2/uk unknown
- 2011-08-26 MX MX2013002323A patent/MX342413B/es active IP Right Grant
- 2011-08-26 PT PT11820759T patent/PT2608809T/pt unknown
- 2011-08-26 ES ES11820759T patent/ES2739505T3/es active Active
- 2011-08-26 CN CN201410816632.5A patent/CN104530238B/zh active Active
- 2011-08-26 EP EP11820759.6A patent/EP2608809B1/en active Active
- 2011-08-26 KR KR1020177006624A patent/KR101930179B1/ko active Active
- 2011-08-26 NZ NZ701444A patent/NZ701444A/en not_active IP Right Cessation
- 2011-08-26 BR BR112013004579-5A patent/BR112013004579B1/pt not_active IP Right Cessation
- 2011-08-26 AP AP2013006743A patent/AP3948A/en active
- 2011-08-26 US US13/219,523 patent/US8377443B2/en active Active
- 2011-08-26 MA MA35741A patent/MA34527B1/fr unknown
- 2011-08-26 AP AP2016009448A patent/AP2016009448A0/en unknown
- 2011-08-26 NZ NZ606880A patent/NZ606880A/en not_active IP Right Cessation
- 2011-08-26 TR TR2019/10348T patent/TR201910348T4/tr unknown
- 2011-08-26 CA CA2808418A patent/CA2808418C/en active Active
- 2011-08-26 WO PCT/US2011/049448 patent/WO2012027721A2/en not_active Ceased
- 2011-08-26 PH PH1/2013/500347A patent/PH12013500347A1/en unknown
- 2011-08-26 KR KR1020137007599A patent/KR101518144B1/ko active Active
- 2011-08-26 SI SI201131732T patent/SI2608809T1/sl unknown
- 2011-08-26 AU AU2011293125A patent/AU2011293125B2/en active Active
- 2011-08-26 PE PE2013000344A patent/PE20131376A1/es active IP Right Grant
- 2011-08-26 SG SG2013011341A patent/SG188224A1/en unknown
-
2012
- 2012-09-14 US US13/619,318 patent/US8501916B2/en active Active
-
2013
- 2013-02-07 IL IL224614A patent/IL224614A/en active IP Right Grant
- 2013-02-20 ZA ZA2013/01338A patent/ZA201301338B/en unknown
- 2013-02-22 CO CO13036730A patent/CO6680656A2/es unknown
- 2013-02-25 CL CL2013000535A patent/CL2013000535A1/es unknown
- 2013-03-21 CR CR20130132A patent/CR20130132A/es unknown
- 2013-03-25 EC ECSP13012525 patent/ECSP13012525A/es unknown
- 2013-07-03 US US13/935,352 patent/US9260532B2/en active Active
- 2013-07-03 US US13/935,370 patent/US9120863B2/en active Active
-
2015
- 2015-08-28 US US14/839,503 patent/US20160159923A1/en not_active Abandoned
- 2015-09-25 ZA ZA2015/07081A patent/ZA201507081B/en unknown
- 2015-10-23 JP JP2015208653A patent/JP6198797B2/ja active Active
-
2016
- 2016-01-11 US US14/992,678 patent/US20160122437A1/en not_active Abandoned
- 2016-08-25 PH PH12016501691A patent/PH12016501691A1/en unknown
-
2017
- 2017-08-22 JP JP2017159712A patent/JP6435381B2/ja active Active
- 2017-09-05 US US15/695,765 patent/US20180086845A1/en not_active Abandoned
- 2017-10-29 IL IL255300A patent/IL255300A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016020389A5 (enExample) | ||
| CN103958544B (zh) | 针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体 | |
| JP2017501129A5 (enExample) | ||
| JP2015506944A5 (enExample) | ||
| JP2018501197A5 (enExample) | ||
| RU2009120052A (ru) | Композиции и способы связывания сфингозин-1-фосфата | |
| JP2015503909A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| RU2016123839A (ru) | Новые модуляторы и способы их применения | |
| JP2015534564A5 (enExample) | ||
| JP2016520520A5 (enExample) | ||
| JP7011939B2 (ja) | ヒト抗－ｆｇｆｒ４抗体 | |
| US20150266967A1 (en) | Superior efficacy of cd37 antibodies in cll blood samples | |
| RU2016137256A (ru) | АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb | |
| JP2018529661A5 (enExample) | ||
| JPWO2020059847A5 (enExample) | ||
| WO2016092082A1 (en) | Method for the treatment of idiopathic pulmonary fibrosis | |
| JP2017528129A5 (enExample) | ||
| JP2017529324A5 (enExample) | ||
| JP2017526618A5 (enExample) | ||
| RU2016148616A (ru) | Анти-lgr5 антитела и их применение | |
| EP4243827A1 (en) | Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer | |
| US20230030597A1 (en) | Methods of treating cancer by the use of pd-1 axis inhibitors and anti-periostin antibodies | |
| CA3169455A1 (en) | Combinations of egfr inhibitors and ror1 inhibitors for the treatment of cancer | |
| RU2018137817A (ru) | Фармацевтическая композиция для лечения и/или предотвращения злокачественных опухолей |